Medartis Holding AG (SIX: MED) announced that its shareholders approved all substantive proposals of the Board of Directors with significant majorities at the Annual General Meeting (AGM) held on April 23, 2026, in Basel, Switzerland. The AGM saw strong participation, with 77.4% of total share capital represented, reflecting robust shareholder engagement.
All proposals by the Board of Directors were approved with over 90.9% support. Seven board members standing for re-election received resounding endorsement, each securing more than 93.8% of represented votes. Yang Xu was newly elected to the Board of Directors with 99.7% endorsement and will join the Finance and Audit Committee, bringing fresh expertise to the company's financial oversight.
Shareholders granted discharge to board members for their governance during the 2025 term and approved the proposed maximum total remuneration for both the Board of Directors and the Executive Management Board, including fixed and variable components. The 2025 management report and annual financial statements received nearly unanimous approval at 99.99%, while the remuneration report was approved by 91.0% in a consultative vote. Additionally, the sustainability report gained strong endorsement with 99.2% of represented shares, confirming Medartis' commitment to transparent environmental, social, and governance (ESG) practices.
Chairman Marco Gadola will continue to lead the Board. After two years with Medartis, Jennifer Dean has decided not to stand for re-election. The assembly also confirmed Damien Tappy and Marco Gadola as members of the Human Resources and Compensation Committee (HRCC), ensuring continuity in the oversight of the company's human capital strategy. The Board of Directors now consists of eight members: Marco Gadola (Chairman), Dr. h.c. Thomas Straumann (Vice Chairman), Willi Miesch, Damien Tappy, Nadia Tarolli Schmidt, Ciro Roemer, Martha Shadan, and Yang Xu.
In accordance with the board's proposal, shareholders confirmed the re-election of Neovius AG as independent voting representative and Ernst & Young AG as statutory auditors. For a detailed listing of all resolutions at the 2026 Annual General Meeting, please visit this link.
Medartis also confirmed upcoming dates for its investor and corporate calendar. On June 4, 2026, Medartis will host an investor event in Basel, held on the fringes of the FESSH Hand Surgery Congress. The event is open to institutional investors and will provide an opportunity to engage with the company's management. The first-half 2026 results will be published on August 18, 2026, followed by a customary analyst and media briefing. The next Annual General Meeting is scheduled for April 22, 2027, at the company's headquarters in Basel.
These strong shareholder approvals and the election of Yang Xu signal continued confidence in Medartis' strategic direction and governance. For business leaders in the medical device industry, Medartis' transparent ESG reporting and robust financial oversight underscore the importance of sustainability and accountability in corporate governance. The upcoming investor event and results publication will provide further insights into the company's performance and strategic priorities.
